JAMP ALMOTRIPTAN 6.25 MG
ALMOTRIPTAN (ALMOTRIPTAN MALATE) : 6.25 MG · DIN 02556022 · JAMP PHARMA CORPORATION
Health Canada status: APPROVED
What is JAMP ALMOTRIPTAN?
JAMP ALMOTRIPTAN 6.25 MG contains ALMOTRIPTAN (ALMOTRIPTAN MALATE) : 6.25 MG. It is listed in the Health Canada Drug Product Database under DIN 02556022, held by JAMP PHARMA CORPORATION, supplied as TABLET for ORAL administration. Health Canada currently lists it as approved, status dated 05-Mar-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02556022 |
|---|---|
| Brand name | JAMP ALMOTRIPTAN |
| Generic / active ingredient | ALMOTRIPTAN (ALMOTRIPTAN MALATE) : 6.25 MG |
| Manufacturer | JAMP PHARMA CORPORATION |
| Strength | 6.25 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N02CC05 ALMOTRIPTAN |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 05-Mar-2025 |
What can be used instead?
Other Canadian products sharing ATC code N02CC05 ALMOTRIPTAN. 6 of 13 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ALMOTRIPTAN | 12.5 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02466821 |
| ALMOTRIPTAN | 12.5 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02424029 |
| MYLAN-ALMOTRIPTAN | 12.5 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02398443 |
| MYLAN-ALMOTRIPTAN | 6.25 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02398435 |
| SANDOZ ALMOTRIPTAN | 12.5 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02405334 |
| TEVA-ALMOTRIPTAN | 12.5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02434849 |
| APO-ALMOTRIPTAN | 12.5 MG | TABLET | APOTEX INC | DORMANT | DIN 02405806 |
| APO-ALMOTRIPTAN | 6.25 MG | TABLET | APOTEX INC | DORMANT | DIN 02405792 |
| AXERT 12.5MG | 12.5 MG | TABLET | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | CANCELLED POST MARKET | DIN 02248129 |
| AXERT 6.25MG | 6.25 MG | TABLET | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | CANCELLED POST MARKET | DIN 02248128 |
Who else supplies ALMOTRIPTAN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ALMOTRIPTAN appears in 26 registered pack listings across 6 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.